DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT04042701. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan (DS-8201a), An Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), In Combination With Pembrolizumab, An Anti-PD-1 Antibody, For Subjects With Locally Advanced/Metastatic Breast Or Non-Small Cell Lung Cancer (NSCLC)
Study identification
- NCT ID
- NCT04042701
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Daiichi Sankyo
- Industry
- Enrollment
- 115 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab Drug
- Trastuzumab deruxtecan (DS-8201a) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 9, 2020
- Primary completion
- Jul 20, 2025
- Completion
- Mar 30, 2027
- Last update posted
- Nov 17, 2025
2020 – 2027
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Univ. of Cali. San Francisco Medical Center | San Francisco | California | 94143 | — |
| Yale Cancer Center | New Haven | Connecticut | 06520 | — |
| Cancer Specialists of North Florida (Cbo) | Jacksonville | Florida | 32256 | — |
| Moffitt Cancer Center | Tampa | Florida | 32256 | — |
| Moffit Cancer Center | Tampa | Florida | 33612 | — |
| Center for Cancer & Blood Disorders | Bethesda | Maryland | 20817 | — |
| Massachusetts General Hospital Cancer Center | Boston | Massachusetts | 02114 | — |
| Siteman Cancer Center-Washington University | St Louis | Missouri | 63110 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Hope Cancer Center of East Texas | Tyler | Texas | 75701 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04042701, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 17, 2025 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04042701 live on ClinicalTrials.gov.